AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
96,100
Employees96,100
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
96,100
Employees96,100

AZN Key Statistics

Market cap
245.96B
Market cap245.96B
Price-Earnings ratio
25.18
Price-Earnings ratio25.18
Dividend yield
1.85%
Dividend yield1.85%
Average volume
3.92M
Average volume3.92M
High today
$162.75
High today$162.75
Low today
$153.41
Low today$153.41
Open price
$157.09
Open price$157.09
Volume
16.31M
Volume16.31M
52 Week high
$212.71
52 Week high$212.71
52 Week low
$145.79
52 Week low$145.79

Stock Snapshot

As of today, AstraZeneca(AZN) shares are valued at $157.22. The company's market cap stands at 245.96B, with a P/E ratio of 25.18 and a dividend yield of 1.85%.

On 2026-08-04, AstraZeneca(AZN) stock moved within a range of $153.41 to $162.75. With shares now at $157.22, the stock is trading +2.5% above its intraday low and -3.4% below the session's peak.

Trading activity shows a volume of 16.31M, compared to an average daily volume of 3.92M.

Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $145.79.

Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $145.79.

AZN News

Barron's 4h
More Biotech M&A Is Coming, Whether an AstraZeneca-Bristol Myers Deal Happens or Not

Biotech and Pharma Feature More Biotech M&A Is Coming, Whether an AstraZeneca-Bristol Myers Deal Happens or Not In this article BMY GSK 524715 LLY AZN Bristol M...

More Biotech M&A Is Coming, Whether an AstraZeneca-Bristol Myers Deal Happens or Not
Investor's Business Daily 14h
AstraZeneca Stock Nosedives On Rumored Mega-Merger - Investor's Business Daily

...

AstraZeneca Stock Nosedives On Rumored Mega-Merger - Investor's Business Daily
TipRanks 16h
TD Cowen sees no strategic logic in an AstraZeneca-Bristol Myers merger

TD Cowen analyst Steve Scala doesn’t see logic in combination of AstraZeneca (AZN) and Bristol Myers (BMY). If combined, AstraZeneca’s 2027-2032 sales growth wo...

Analyst ratings

81%

of 31 ratings
Buy
80.6%
Hold
12.9%
Sell
6.5%

More AZN News

Benzinga 17h
AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus

The news took the healthcare sector by storm, and the merger would position AstraZeneca as the world’s fourth-largest drugmaker by market capitalization. Prior...

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus
TipRanks 17h
AstraZeneca’s Elecoglipron Trial: Early Signals for a Future Oral Metabolic Franchise

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confi...

Seeking Alpha 18h
Potential AstraZeneca purchase of Bristol-Myers unlikely for now - analyst

A potential AstraZeneca (AZN) acquisition of Bristol-Myers Squibb (BMY) is unlikely to happen now after a report that the pharma giants have held deal talks, ac...

Potential AstraZeneca purchase of Bristol-Myers unlikely for now - analyst
TipRanks 20h
AstraZeneca Adds Employee Scheme Shares to London Listing

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

Benzinga 21h
Why Is Bristol-Myers Squibb Stock Surging Monday?

The potential combination could create a pharmaceutical giant valued at nearly $400 billion. AstraZeneca holds an estimated market capitalization of $263 billio...

Why Is Bristol-Myers Squibb Stock Surging Monday?
Benzinga 22h
Jim Cramer Senses a 'Fake Out' in Rumored AstraZeneca, Bristol Myers Squibb $400 Billion Mega-Merger

Wall Street Skepticism Meets Pharma Mega-Merger Rumors Reacting to reports of the massive transaction, Cramer asked in a post on X if the ongoing talks were an...

Jim Cramer Senses a 'Fake Out' in Rumored AstraZeneca, Bristol Myers Squibb $400 Billion Mega-Merger
Seeking Alpha 22h
AstraZeneca tops pharma growth rankings while Bristol Myers trails amid merger talks

AstraZeneca (AZN) tops pharmaceutical growth rankings while Bristol Myers Squibb (BMY) trails, as the two drugmakers reportedly explore a potential merger that...

AstraZeneca tops pharma growth rankings while Bristol Myers trails amid merger talks

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.